Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis

被引:76
作者
Nakano, Chikako [1 ]
Hamano, Takayuki [1 ,2 ]
Fujii, Naohiko [3 ]
Obi, Yoshitsugu [1 ]
Matsui, Isao [1 ]
Tomida, Kodo [4 ]
Mikami, Satoshi [5 ]
Inoue, Kazunori [1 ]
Shimomura, Akihiro [1 ]
Nagasawa, Yasuyuki [1 ]
Okada, Noriyuki [6 ]
Tsubakihara, Yoshiharu [6 ]
Rakugi, Hiromi [1 ]
Isaka, Yoshitaka [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka, Japan
[2] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Pennsylvania, PA USA
[3] Hyogo Prefectural Nishinomiya Hosp, Dept Internal Med, Hyogo, Japan
[4] Kansai Rosai Hosp, Dept Internal Med, Hyogo, Japan
[5] Higashi Kohri Hosp, Dept Internal Med, Osaka, Japan
[6] Osaka Gen Med Ctr, Dept Hypertens & Nephrol, Osaka, Japan
关键词
Chronic kidney disease; Cardiovascular disease; Fibroblast growth factor 23; Mineral metabolism; Risk stratification; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; SERUM ALKALINE-PHOSPHATASE; VITAMIN-D LEVELS; RENAL-FUNCTION; VASCULAR CALCIFICATION; DIETARY PHOSPHATE; ALL-CAUSE; MORTALITY; RISK;
D O I
10.1016/j.bone.2012.02.634
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Low 25-hydroxyvitamin D (25D), increased levels of fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and alkaline phosphatase (ALP) were reported to be risk factors for mortality in chronic kidney disease (CKD). However, the independent associations of these factors with cardiovascular disease (CVD), the leading cause of death among CKD patients, remain unclear. Our purpose was to identify which of these factors predict incident CVD in CKD. Methods: In this prospective cohort study, we enrolled 738 predialysis outpatients in the two nephrology departments. We employed Cox proportional hazards analyses to elucidate predictors of the endpoint, defined as fatal or non-fatal cardiovascular event requiring hospitalization. Multiple imputation was performed for missing values. Results: Mean estimated glomerular filtration rate (eGFR) was 35 mL/min/1.73 m(2). During a median duration of 4.4 years, 86 patients developed the endpoint, of whom 62 patients achieved it before the initiation of dialysis. Multivariable analyses revealed that high serum intact FGF23 levels predicted the outcome preceding dialysis initiation (hazard ratio (HR) per InFGF23 (SD), 1.64 (1.27-2.30)), while 250, PTH, and bone-specific ALP did not. Adding FGF23 to the conventional model of age, sex, diabetes, prior CVD, pulse pressure, and eGFR, led to a net reclassification improvement of 6.87% (P=0.04). Not censoring the patients at the start of dialysis and continuing follow-up even after dialysis, FGF23 levels did not predict the outcome (HR, 1.16 (0.91-1.48)). Complete case analyses yielded similar results. Conclusions: Intact FGF23 levels in predialysis CKD predicted incident cardiovascular events requiring hospitalization before starting dialysis, but did not predict events during the entire follow-up period, including post dialysis initiation. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:1266 / 1274
页数:9
相关论文
共 50 条
  • [21] Fibroblast Growth Factor 23 and Cardiovascular Mortality after Kidney Transplantation
    Baia, Leandro C.
    Humalda, Jelmer K.
    Vervloet, Marc G.
    Navis, Gerjan
    Bakker, Stephan J. L.
    de Borst, Martin H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (11): : 1968 - 1978
  • [22] Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals CHS (Cardiovascular Health Study)
    Ix, Joachim H.
    Katz, Ronit
    Kestenbaum, Bryan R.
    de Boer, Ian H.
    Chonchol, Michel
    Mukamal, Kenneth J.
    Rifkin, Dena
    Siscovick, David S.
    Sarnak, Mark J.
    Shlipak, Michael G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (03) : 200 - 207
  • [23] Association of Fibroblast Growth Factor 23 and Cardiac Mechanics in the Cardiovascular Health Study
    Jain, Keertana
    Katz, Ronit
    Isakova, Tamara
    Kizer, Jorge R.
    Sharma, Shilpa
    Psaty, Bruce M.
    Shah, Sanjiv J.
    Ix, Joachim
    Mehta, Rupal
    KIDNEY360, 2025, 6 (03): : 391 - 399
  • [24] Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults
    Paul, Shejuti
    Wong, Mandy
    Akhabue, Ehimare
    Mehta, Rupal C.
    Kramer, Holly
    Isakova, Tamara
    Carnethon, Mercedes R.
    Wolf, Myles
    Gutierrez, Orlando M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (16):
  • [25] Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels
    Knab, Vanessa M.
    Corbin, Braden
    Andrukhova, Olena
    Hum, Julia M.
    Ni, Pu
    Rabadi, Seham
    Maeda, Akira
    White, Kenneth E.
    Erben, Reinhold G.
    Juppner, Harald
    Christov, Marta
    ENDOCRINOLOGY, 2017, 158 (05) : 1130 - 1139
  • [26] Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease
    Tunon, Jose
    Fernandez-Fernandez, Beatriz
    Carda, Rocio
    Pello, Ana M.
    Cristobal, Carmen
    Tarin, Nieves
    Acena, Alvaro
    Luisa Gonzalez-Casaus, Maria
    Huelmos, Ana
    Alonso, Joaquin
    Lorenzo, Oscar
    Gonzalez-Parra, Emilio
    Hernandez-Gonzalez, Ignacio
    Mahillo-Fernandez, Ignacio
    Lopez-Bescos, Lorenzo
    Egido, Jesus
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (07) : 685 - 693
  • [27] Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure
    Wohlfahrt, Peter
    Melenovsky, Vojtech
    Kotrc, Martin
    Benes, Jan
    Jabor, Antonin
    Franekova, Janka
    Lemaire, Sophia
    Kautzner, Josef
    Jarolim, Petr
    JACC-HEART FAILURE, 2015, 3 (10) : 829 - 839
  • [28] The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
    Cozzolino, Mario
    Mazzaferro, Sandro
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (03) : 404 - 411
  • [29] Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases A Mendelian Randomization Study
    Donovan, Killian
    Herrington, William G.
    Pare, Guillaume
    Pigeyre, Marie
    Haynes, Richard
    Sardell, Rebecca
    Butterworth, Adam S.
    Folkersen, Lasse
    Gustafsson, Stefan
    Wang, Qin
    Baigent, Colin
    Malarstig, Anders
    Holmes, Michael V.
    Staplin, Natalie
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (01): : 17 - 27
  • [30] High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis
    Fang, Yu-Wei
    Wang, Jing-Tong
    Lin, Tzu Yun
    Lee, Chung-Jen
    Jang, Tsrang-Neng
    Tsai, Ming-Hsien
    Liou, Hung-Hsiang
    FRONTIERS IN MEDICINE, 2023, 10